GlassScriptPhysician profile
Tony A Flippin
NPI 1598780652
$940.73
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $122 · 2022: $13.92 · 2023: $25.60 · 2024: $14.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $39.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $39.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $222.59 | 2019-2020 | |
| Eisai INC. | $124.41 | 2019-2020 | |
| Pfizer INC. | $107.96 | 2019-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $99.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.50 | 2019-2020 | |
| Gilead Sciences, INC. | $64.34 | 2019 | |
| Merck Sharp & Dohme LLC | $58.98 | 2019-2020 | |
| Lilly USA, LLC | $52.32 | 2019 | |
| Janssen Biotech, INC. | $25.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 2019 | |
| Foundation Medicine, INC. | $18.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.50 | 2019 | |
| Celgene Corporation | $17.54 | 2019 | |
| Kite Pharma, INC. | $14.12 | 2020 | |
| Incyte Corporation | $12.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Flippin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.